Advancing understanding of treatment through clinical trials

November 4, 2012

Three late-breaking studies presented during the American Society of Nephrology's Annual Kidney Week provide new information on drugs being tested in patients with diabetes or kidney disease.

Hans-Henrik Parving, MD (University of Copenhagen, in Denmark) and his colleagues investigated whether the drug aliskiren might improve the prognosis of with who are at high risk for developing heart and kidney problems. The randomized double-blind ALTITUDE trial included 8561 individuals who received aliskiren (300 mg once daily) or placebo on top of a drug that blocks the renin-angiotensin-aldosterone system (RAAS), a complex that regulates blood pressure and fluid balance. (Drugs that target the RAAS have limited effectiveness in part due to feedback responses, such as compensatory increases in an enzyme called renin. Aliskiren is a direct renin inhibitor and may help overcome these shortcomings because it suppresses the reactive rise in renin activity stimulated by other RAAS blockers.) After an average follow-up of 32.9 months:

  • 17.9% of patients receiving aliskiren and 16.8% of those receiving placebo experienced a heart attack or stroke, developed , or died of cardiovascular disease.
  • Stroke occurred in 3.4% of patients taking aliskiren, compared with 2.7% of patients taking placebo.
  • Patients taking aliskiren experienced significantly increased and hypotension.
"The trial does not support administration of aliskiren on top of standard therapy with RAAS blockade in type 2 diabetic patients at high risk for cardiovascular and renal events, and may even be harmful," the authors concluded.

Another team led by Vicente Torres, MD, PhD (Mayo Clinic) tested the potential of a vasopressin V2 (tolvaptan) to inhibit cyst growth and slow decline in patients with autosomal dominant (ADPKD). This condition causes kidney cysts often associated with pain, hypertension, and kidney failure. The phase 3, multi-center, double-blind, placebo-controlled, 3-year trial included 1445 ADPKD patients who were randomized 2:1 to split dose tolvaptan (45/15, 60/30 or 90/30 mg daily as tolerated) or placebo.

  • Total kidney volume increase over 3 years was halved in patients treated with tolvaptan compared to placebo (2.80%/year versus 5.51%/year).
  • Patients taking tolvaptan were 61% less likely to experience a certain level of worsening kidney function and 36% less likely to experience kidney pain requiring treatment.
  • Tolvaptan slowed the rate of kidney function decline compared with placebo.
"Tolvaptan demonstrated clinically meaningful disease-specific benefits for ADPKD patients which may be clinically meaningful," said Dr. Torres. While the trial findings are encouraging, tolvaptan has not yet been approved for this indication.

A third trial, called EVOLVE, was designed to test the hypothesis that treatment with cinacalcet compared with placebo reduces the risk of premature death or non-fatal heart-related events among dialysis patients with secondary hyperparathyroidism. (Secondary hyperparathyroidism, when the parathyroid gland produces excess amounts of parathyroid hormone, arises in most patients with chronic disease as their disease progresses. It can lead to a number of complications, including cardiovascular problems.) Results from analyses using multivariable adjustment and censoring data 6 months after patients stopped taking the drug will be presented, along with safety data, by Glenn Chertow, MD (Stanford University School of Medicine).

Explore further: Promising kidney drug fails in large clinical trial

More information: Study co-authors for "The Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)" (abstract 6313) include Barry M. Brenner, MD, John Mcmurray, Dick de Zeeuw, MD, PhD, Steven Mark Haffner, MD, Scott D. Solomon, MD, Nish Chaturvedi, Frederik I. Persson, MD, Akshay Suvas Desai, Maria Nicolaides, and Marc A. Pfeffer, MD, PhD.

Study co-authors for "Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Trial" (abstract 6357) include Arlene B. Chapman, MD, Olivier Devuyst, MD, PhD, Ron T. Gansevoort, MD, PhD, Jared J. Grantham, MD, Eiji Higashihara, MD, Ronald D. Perrone, MD, Holly B. Krasa, John Ouyang, PhD, Osamu Sato, and Frank S. Czerwiec, MD, PhD.

Study co-authors for "Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE) trial" (abstract 6450) include Geoffrey A. Block, MD, Ricardo Correa-Rotter, MD, Tilman B. Drueke, MD, Jurgen Floege, MD, William G. Goodman, MD, Christian Mix, MD, Marie-Louise Trotman, Yumi Kubo, Charles A. Herzog, MD, Gerard M. London, MD, Kenneth Mahaffey, MD, Sharon M. Moe, MD, David C. Wheeler, MD, and Patrick S. Parfrey, MD.

Related Stories

Promising kidney drug fails in large clinical trial

October 27, 2011

What was hoped to be a promising new drug to protect the kidneys has failed to benefit diabetes patients with kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology ...

Vitamin B derivative helps diabetics with mild kidney disease

October 27, 2011

A vitamin B6 derivative may help slow or prevent the progression of mild kidney disease in patients with diabetes, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). ...

Median follow-up results from the ALTITUDE study

August 27, 2012

Preliminary results from the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) do not support administration of aliskiren on top of standard therapy with renin-angiotensin-aldosterone system (RAAS) ...

Recommended for you

Monkeys in Asia harbor virus from humans, other species

November 19, 2015

When it comes to spreading viruses, bats are thought to be among the worst. Now a new study of nearly 900 nonhuman primates in Bangladesh and Cambodia shows that macaques harbor more diverse astroviruses, which can cause ...

One-step test for hepatitis C virus infection developed

November 14, 2015

UC Irvine Health researchers have developed a cost-effective one-step test that screens, detects and confirms hepatitis C virus (HCV) infections. Dr. Ke-Qin Hu, director of hepatology services, will present findings at the ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.